Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
Improvement in vision-related quality-of-life using the NEI-VFQ-9 over 1-year in the Manhattan Vision Screening and Follow-up Study (NYC-SIGHT).
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hark Lisa A, Gorroochurn Prakash, Tang Haotian, Torres Desiree R, Blackburn Brendan, Maruri Stefania C, Diamond Daniel F, Harizman Noga, Wang Qing, Wang Yujia, Liebmann Jeffrey M, Cioffi George A, Horowitz Jason D, Park Lisa
Аннотация
PURPOSE: To examine the nine-item National Eye Institute Vision Function Questionnaire (NEI-VFQ-9) scores at baseline and 12 months in participants enrolled in the Manhattan Vision Screening and Follow-up Study (NYC-SIGHT) and determine factors associated with improvements in vision-related quality-of-life (VRQOL).
METHODS: Retrospective review of NEI-VFQ-9 scores at baseline and 12-month follow-up in a community-based eye health screening study conducted in Upper Manhattan, New York. Participants were age ≥ 40 years and older, living independently in public/affordable housing developments and able to provide informed consent. Paired t-tests compared baseline and 12-month NEI-VFQ-9 composite and sub-scores and a multivariable linear regression model identified significant predictors of improvement in quality-of-life at the 95% confidence interval (CI).
RESULTS: A total of 515 participants completed both the NEI-VFQ-9 at baseline and 12-months. Significant increases in the composite NEI-VFQ-9 score were seen with general vision, near vision tasks, and role limitation (P < 0.001). Multivariable linear regression showed that being unemployed was associated with a statistically significant increase in NEI-VFQ-9 composite score (β = 5.6, 95% CI: 0.5,10.7, P = 0.033), and the absence of ocular conditions was negatively associated with improvement in the composite score over 12 months (β = -5.4, 95% CI: -10.3, -0.5, P = 0.031).
CONCLUSIONS: These results can help researchers, clinicians, and eye health professionals better understand the factors associated with VRQOL outcomes in underserved populations utilizing the NEI-VFQ-9. Community-based vision research clinical trials can easily incorporate the NEI-VFQ-9 into baseline and follow-up instruments to assess VRQOL for future comparisons.
METHODS: Retrospective review of NEI-VFQ-9 scores at baseline and 12-month follow-up in a community-based eye health screening study conducted in Upper Manhattan, New York. Participants were age ≥ 40 years and older, living independently in public/affordable housing developments and able to provide informed consent. Paired t-tests compared baseline and 12-month NEI-VFQ-9 composite and sub-scores and a multivariable linear regression model identified significant predictors of improvement in quality-of-life at the 95% confidence interval (CI).
RESULTS: A total of 515 participants completed both the NEI-VFQ-9 at baseline and 12-months. Significant increases in the composite NEI-VFQ-9 score were seen with general vision, near vision tasks, and role limitation (P < 0.001). Multivariable linear regression showed that being unemployed was associated with a statistically significant increase in NEI-VFQ-9 composite score (β = 5.6, 95% CI: 0.5,10.7, P = 0.033), and the absence of ocular conditions was negatively associated with improvement in the composite score over 12 months (β = -5.4, 95% CI: -10.3, -0.5, P = 0.031).
CONCLUSIONS: These results can help researchers, clinicians, and eye health professionals better understand the factors associated with VRQOL outcomes in underserved populations utilizing the NEI-VFQ-9. Community-based vision research clinical trials can easily incorporate the NEI-VFQ-9 into baseline and follow-up instruments to assess VRQOL for future comparisons.